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Recombinant human glucose 6-phosphate dehydrogenase
(G6PD) has been crystallized and its structure solved by
molecular replacement. Crystals of the natural mutant R459L
grow under similar conditions in space groups P212121 and
C2221 with eight or four 515-residue molecules in the
asymmetric unit, respectively. A non-crystallographic 222
tetramer was found in the C2221 crystal form using a 4 AÊ
resolution data set and a dimer of the large  +  domains of
the Leuconostoc mesenteroides enzyme as a search model.
This tetramer was the only successful search model for the
P212121 crystal form using data to 3 AÊ . Crystals of the deletion
mutant G6PD grow in space group F222 with a monomer in
the asymmetric unit; 2.5 AÊ resolution data have been
collected. Comparison of the packing of tetramers in the
three space groups suggests that the N-terminal tail of the
enzyme prevents crystallization with exact 222 molecular
symmetry.
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1. Introduction
Glucose 6-phosphate dehydrogenase (G6PD) catalyses the
®rst committed step in the pentose phosphate pathway; it
converts glucose 6-phosphate (G6P) to 6-phosphoglucono--
lactone with the reduction of NADP+ to NADPH. The
NADPH it generates has been implicated in protecting the
cells against oxidative damage. This is especially important for
erythrocytes, in which G6PD is the main enzyme providing the
reducing equivalent. Further, recent reports have shown a
close correlation between the activity of G6PD and cell
growth (Stanton et al., 1991; Tian et al., 1998). It has been
suggested that stimulation of cell growth by epidermal growth
factor or platelet-derived growth factor releases bound G6PD
from the cytoskeleton and activates the enzyme. In those
studies, NADPH has been identi®ed as indispensable for
regulating the redox potential and, therefore, cell growth.
Multiple alignment (Barton, 1990) of all the 35 known
amino-acid sequences of G6PD clearly shows that there is
greater than 48% identity between G6PDs from eukaryotic
organisms.1 The single known exception is the enzyme from
1 23 sequences: human (Persico et al., 1986), rat (Ho et al., 1988), mouse
(Toniolo et al., 1991), wallaroo (Loebel et al., 1995), Fugu rubripes (Mason et
al., 1995), Drosophila melanogaster (Fouts et al., 1988; Eanes et al., 1998a),
Drosophila yakuba (Eanes et al., 1998b), Ceratitis capitata (Scott et al., 1993),
plastid and chloroplast potato (Schaewen et al., 1995), Medicago sativa
(Fahrendorf et al., 1995), ®ssion yeast (Badcock et al., 1997), Pichia jadinii
(Jeffery et al., 1993), Saccharomyces cerevisiae (Nogae & Johnston, 1990),
Kluyeromyces marxians lactis (Wesolowski-Louvel et al., 1996), Emericella
nidulans (Schaap et al., 1997), Aspergillus niger (van den Broek et al., 1995),
Arabidopsis thaliana (Fink et al., 1995), Nicotiana tabacum (Knight & Emes,
1996), Nostoc sp. ATCC 29133 (Summers et al., 1995), Synechocystis PCC 6803
(Kaneko et al., 1996), Anabaena PCC 7120 (Newman et al., 1995) and C.
elegans (Wilson et al., 1994).
the malarial parasite Plasmodium falciparum, which has an
extra 400 residues at the N-terminus (O'Brien et al., 1994).
There is better than 30% identity for all sequences compared
so far including the known prokaryotic sequences.2 The 33%
sequence identity between the Leuconostoc mesenteroides and
human G6PDs is high enough to indicate a common fold. The
eight-residue peptide RIDHYLGK (residues 198±205 in the
human enzyme), which is completely conserved among these
sequences, has been shown to be important in binding
substrate (Bhadbhade et al., 1987; Camardella et al., 1988;
Bautista et al., 1995), and a modi®ed nucleotide-binding
®ngerprint, GxxGDLA, (residues 42±48 in the human
enzyme) has been associated with coenzyme binding (Levy et
al., 1996). The functions of these residues have been eluci-
dated by the 2 AÊ resolution structure of the dimeric L.
mesenteroides G6PD and further conserved active-site resi-
dues identi®ed (Rowland et al., 1994). Each subunit of the L.
mesenteroides G6PD contains a small domain which shows a
classic ±± dinucleotide-binding fold, and a larger  + 
domain dominated by nine antiparallel sheet strands. The
substrate-binding site is located in the cleft between the two
domains. The dimer is extended with coenzyme-binding
domains distant from one another; one face of the extended
molecule is slightly concave and the other (the `back' face)
convex.
In the human, both the homodimer and tetramer are
functional forms of G6PD. This is different from L. mesen-
teroides G6PD, which exists only as a dimer. The equilibrium
between dimer and tetramer is affected by ionic strength and,
markedly, by pH (Cohen & Rosemeyer, 1969). At pH above
7.3, the equilibrium shifts towards the formation of the dimer
and below 7.3 towards the tetramer. Biochemical analysis and
electron microscopy have shown equilibria only between
tetramer and dimer and between dimer and monomer
(Bonsignore et al., 1971; Wrigley et al., 1972). It seems that the
tetramer is formed by association of two dimers instead of four
monomers. It has also been shown that human G6PD is able to
change reversibly from an active dimer to an inactive
monomer at high NADPH/NADP+ ratios (Kirkman &
Hendrickson, 1962; Bonsignore et al., 1971). NADP+ is
necessary for converting the inactive monomers into cataly-
tically active dimers or tetramers; this has been interpreted in
terms of `structural' as well as active-site NADP+ being bound
to the dimeric enzyme (Bonsignore et al., 1971; De Flora,
Morelli, Benatti et al., 1974; De Flora, Morelli & Giuliano,
1974).
G6PD de®ciency is one of the most common enzymopathies
and affects 400 million people worldwide. The associated
clinical symptoms are neonatal jaundice, haemolytic anaemia
and favism. In some rare cases, chronic non-spherocytic
haemolytic anaemia (CNSHA) results; the variants exhibiting
CNSHA are designated as Class I. Over 400 different variants
of G6PD have been reported and more than 100 mutations
have been identi®ed in its cDNA (Persico et al., 1986; Mason,
1996; Vulliamy et al., 1997). A human homology model based
on the structure of the L. mesenteroides apo-enzyme and a
14-sequence multiple alignment (Naylor et al., 1996) reveals
that most of the Class I mutations, which are characterized by
very low enzyme activity and thermostability, are located in or
near the dimer interface. These mutations weaken the integ-
rity of the dimer by affecting both the hydrophobic and
charge±charge interactions.
The two mutant enzymes studied here are the polymorphic
variant G6PD Canton (R459L; McCurdy et al., 1966; Stevens et
al., 1990; Au, 1997) and the deletion mutant G6PD without
the N-terminal 25 residues. G6PD R459L is the most common
variant in Hong Kong and South China, accounting for about a
third of the G6PD de®ciency in this area where 4±6% of the
male population are affected; it has been shown to have a
speci®c activity about 15% that of the wild-type enzyme and a
twofold higher af®nity for the substrate G6P and the coen-
zyme analogue deamino-NADP (Chiu et al., 1991). The puri-
®ed recombinant enzyme used in this study also shows
indistinguishable biochemical characteristics from those of the
enzyme partially puri®ed from haemolysates (Au, 1997). The
mutant G6PD is not a natural variant, but was made both in
the hope of growing high-quality crystals with fewer subunits
in the asymmetric unit and to obtain information concerning
the function of the N-terminal residues. These are poorly
conserved between species and are absent from many G6PDs,
including that of L. mesenteroides. This mutant enzyme has
similar kinetic properties to those of the wild-type enzyme but
is more thermostable. Here, we present the crystallization of
these mutants, the dif®culties encountered and the ultimate
success in molecular replacement, even without recourse to
the diffraction data of the mutant G6PD. We also report a
preliminary crystallographic study of these enzymes in terms
of the crystal packing.
2. Materials and methods
2.1. Preparation of G6PD R459L
Unless stated otherwise, all DNA manipulations leading to
both mutant enzymes were carried out according to standard
procedures (Sambrook et al., 1989). A recombinant expression
plasmid encoding the entire normal human G6PD coding
region was constructed (Au, 1997) from the normal human
G6PD cDNA clone, pGD-T-5B (Persico et al., 1986). The
mutant G6PD R459L was made using in vitro directed
mutagenesis. The expression of recombinant G6PD in E. coli
DF213 (G6PD-de®cient strain) was induced by growth in the
presence of 4 mM IPTG. The culture medium contained 0.1 M
KH2PO4, 0.015 M (NH4)2SO4, 80 mM MgSO4.7H2O and 2 mM
FeSO4.7H2O pH 7.0, 4 mg ml
ÿ1 glucose, 25 mg mlÿ1 histidine
and 25 mg mlÿ1 methionine. Harvested cells grown from 1 l
culture were resuspended in 0.1 M Tris±HCl, 5 mM EDTA,
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2 11 sequences: Leuconostoc mesenteroides (Lee et al., 1991), Leuconostoc
mesenteroides dextranicus (Jarsch & Lang, 1994), Escherichia coli (Rowley &
Wolf, 1991), Zymomonas mobilis (Barnell et al., 1990), Erwinia chrysanthemi
(Hugouvieux-Cotte-Pattat & Robert-Baudouy, 1994), Synechococcus PCC
7942 (Scanlan et al., 1992), Bacillus sp. HT-3 (Sagai et al., 1992), Haemophilus
in¯uenzae (Fleischmann et al., 1995), Haemophilus actinomycetemcomitans
(Yoshida et al., 1997), Helicobacter pylori (Tomb et al., 1997) and
Mycobacterium tuberculosis (Cole et al., 1998).
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3 mM MgCl2, 0.1% mercaptoethanol and proteinase inhibitors
(0.3 mM PMSF, 1 mM aminocaproic acid and 3 mg mlÿ1
aprotinin). Cell lysis was followed by ultracentrifugation at
40000 rev minÿ1 for 1 h at 277 K before running the lysate
through a 2050-ADP Sepharose af®nity column. The enzyme
was eluted with the resuspension buffer containing 100 mM
NADP+. The conditions of puri®cation used have been
described by Bautista et al. (1992).
2.2. Expression and puri®cation of DG6PD
Site-directed mutagenesis was carried out using the Trans-
former mutagenesis kit obtained from Clontech and used
according to the manufacturer's recommendations. The
template for mutagenesis was a plasmid consisting of the
BamHI/XhoI fragment of G6PD cDNA cloned into pUC19.
Using the oligonucleotide 50-TTCCAGGGCGATGC-
CATGGTTCAGTCGGATAC-30, the sequence 50-TTCCAT-30
was changed to 50-ATGGTT-30. This changed residues 26 and
27 from FH to MV and introduced an NcoI restriction site
50-CCATGG-30. The selection primer 50-CGGCCAGTGA-
TATCGAGCTC-30 changed the EcoRI site in pUC19 into an
EcoRV site. After mutagenesis, the truncated NcoI fragment
was cloned into the pKKG6PD expression vector in place of
the full-length NcoI fragment.
The use of the G6PD de®cient E. coli strain DR612
[pgi::Tn10, (Zeb) HB351] (Fraenkel, 1968) and the expres-
sion plasmid pKKG6PD for the production of recombinant
G6PD have been described previously (Bautista et al., 1992).
The methods used for puri®cation and biochemical analysis of
the enzyme again follow previously described procedures
(Bautista et al., 1992).
2.3. Crystallization
Puri®ed G6PD R459L protein solution was dialysed with
10 mM Tris±HCl buffer pH 7.6 containing 0.5 mM EDTA,
40 mM NADP+ and the protease inhibitors as mentioned
above. Two crystal forms with different space groups grew
under similar conditions. For type I crystals, the ®nal
concentration of NADP+ in the protein solution was set at
100 mM. The hanging-drop vapour-diffusion method was used,
in which 1 ml protein solution (10 mg mlÿ1) was mixed with an
equal volume of the reservoir solution containing 0.1 M
sodium citrate, 0.05 M glycolic acid pH 5.8 and 10±15% PEG
3350. Small crystals, less than 0.2 mm in the largest dimension,
grew at 293 K after 3 d, and microseeding was used in order to
obtain larger crystals for X-ray diffraction. For type II crystals
of G6PD R459L, protein solution was prepared as for the type
I crystal, except that NADP+ was replaced by 100 mM thio-
NADP+. The same crystallization buffer was used; after
microseeding, type II crystals grew in the same drops as type I
crystals, which were more predominant. For G6PD, puri®ed
protein was concentrated to 5 mg mlÿ1 for hanging-drop
crystallization in which 2 ml of protein solution was mixed with
2 ml of reservoir buffer containing 0.05 or 0.10 M Tris±HCl pH
7.5±8.2 and 10±16% PEG 4000. Crystals with axial ratios about
1:3:12 grew after a few weeks.
2.4. Data collection
X-ray diffraction data for the R459L crystals were collected
at CLRC Daresbury Laboratory Synchrotron Radiation
Source on stations 9.6 (wavelength 0.87 AÊ ) and 7.2 (wave-
length 1.488 AÊ ) for type I crystals and on station 9.6 for the
type II crystal. Subsequently, a 3 AÊ data set was collected
using another type I R459L crystal on station 7.2. Crystals
were ¯ash-frozen in cryoprotectant containing the crystal-
lization buffer, 50 mM NADP+ and 25% glycerol; an Oxford
Cryosystems Cryostream (Cosier & Glazer, 1986), set to
100 K, was used. A typical diffraction image is shown in Fig. 1.
Images were processed using DENZO (Otwinowski & Minor,
1997) and the data merged and scaled using SCALA and
AGROVATA from the CCP4 package (Collaborative
Computational Project, Number 4, 1994). For the G6PD
crystal, a 2.5 AÊ data set was collected at station 9.6 at 100 K
from a crystal soaked in crystallization buffer containing 20%
glycerol and ¯ash-frozen. Images were processed using
MOSFLM (Leslie, 1992) and the data merged and scaled as
before.
2.5. Structure determination
Self-rotation functions were calculated in spherical polar
angles using the CCP4 program POLARRFN. For molecular
replacement, different programs were tried, including AMoRe
(Navaza, 1994) supplied from the CCP4 program suite, an
automated package of AMoRe which includes a no-overlap
¯ag and X-PLOR (BruÈ nger, 1992b). SIGMAA (Read, 1986)
weighted terms were input to DM (Cowtan, 1994) to calculate
non-crystallographic symmetry (NCS) averaged, solvent-¯at-
Figure 1
X-ray diffraction image from type I R459L G6PD, crystal-to-detector
distance 217 mm, oscillation range 1. Circles are drawn at 12, 6, 4 and
3 AÊ resolution.
tened, histogram-matched electron-density maps. Test sets
(5% of the data) were selected for structure validation
(BruÈ nger, 1992a). The molecular graphics display program O
(Jones & Kjeldgaard, 1997) was used for model building and
X-PLOR was used for re®nement.
3. Results and discussion
3.1. DG6PD: preparation and properties
Site-directed mutagenesis was used to create an NcoI site at
codons 26 and 27 of human G6PD in the expression vector
pKKG6PD. The mutagenesis changed the encoded amino-acid
sequence DAFH to DAMV so that the DNA encoding amino
acids 1±25 could be excised as a small NcoI fragment. The
expression vector thus codes for a protein beginning Met, Val
and containing the normal human G6PD sequence from
residue 27. After cleavage of the initiator methionine,
G6PD, like the L. mesenteroides G6PD, has an N-terminal
valine followed by ten residues before the motif GxxGDL (see
Fig. 2) which is conserved in all known G6PD sequences. The
yield of G6PD (units per millilitre of crude bacterial lysate)
was as high as or higher than that routinely observed with the
normal enzyme. The speci®c activity of G6PD (assayed in
0.25 M Tris±borate pH 8), 216  24 IU mgÿ1, was in the same
range as that of the normal enzyme (220  21 IU mgÿ1;
Bautista et al., 1992). The Km value for NADP (26  2 mM)
was approximately double that of the normal enzyme
(12  2 mM; Bautista et al., 1992), while that for G6P was
within the normal range.
3.2. Crystallization, data collection and processing
The conditions used to grow crystals of G6PD R459L were
determined by modifying a procedure which had been devised
for crystallization of recombinant normal human G6PD
(G6PD B). Attempts to grow human crystals which diffracted
beyond 10 AÊ resolution had been made for more than ten
years in this (and other) laboratories. Poor-quality crystals of
recombinant G6PD B could be grown in PEG 4000 and
acetate; quality could be improved by changing to PEG 3350
and citrate together with another hydroxy acid. G6PD B did
not grow reproducibly but microseeding was possible (Naylor,
1996). Crystals of the variant R459L grew more reliably than
did those of the wild-type enzyme and diffraction was more
reproducible.
The statistics of all data sets are summarized in Table 1. For
G6PD R459L, both data sets 1 and 2 gave a primitive
orthorhombic cell on autoindexing. However, not
all axial re¯ections were sampled in these data sets
and some ambiguity remained concerning the
space group of the type I crystals, which was
assigned as P2(1)2(1)2(1). An estimate of the
solvent content of the crystals (Matthews, 1968)
indicated there were probably eight G6PD mole-
cules in each asymmetric unit. It was expected that
they would be arranged in two tetramers at the pH
of the crystallization buffer, which was below 7.3.
With a calculated molecular weight of 59.2 kDa
for a subunit and VM = 3.04 AÊ
3 Daÿ1, the solvent
content was found to be 59.5%. The 3 AÊ resolu-
tion data set showed systematic absences for the
h00, 0k0 and 00l re¯ections for h, k, l = 2n + 1; the
space group was con®rmed as P212121. This data
set was then merged with data sets 1 and 2.
The type II crystal (data set 3) was shown to
have a centred orthorhombic cell; sampling of
the 00l re¯ections was incomplete in this 86%
complete data set. The space group was assigned
as C222(1), and the crystal solvent content was
calculated to be 61.2% and VM = 3.17 AÊ
3 Daÿ1
with four G6PD molecules in the asymmetric
unit.
The 2.5 AÊ data set collected from the G6PD
crystal was autoindexed in space group F222. The
asymmetric unit consists of only one G6PD
molecule in the asymmetric unit, with VM =
2.53 AÊ 3 Daÿ1; the solvent content was calculated
to be 51.4%. The lower solvent content may
explain why crystals of this mutant diffract to a
higher resolution.
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Figure 2
(a) The N-terminal amino-acid sequence of G6PD from L. mesenteroides (Lee et al.,
1991), D. melanogaster (Fouts et al., 1988) and human (Persico et al., 1986). The fourth
line shows the sequence of the arti®cial mutant G6PD. (b) The upper part shows the
DNA and amino-acid sequence of the N-terminal end of human G6PD. The lower part
shows the oligonucleotide used to introduce an NcoI site into the sequence and
illustrates the change in derived amino-acid sequence from DAFH to DAMV. This new
methionine residue becomes the initiation codon of G6PD after cloning into the
expression vector pKKG6PD. NcoI sites CCATGG are boxed.
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3.3. Structure solution by molecular replacement
A self-rotation function was calculated using the 3.4 AÊ
P2(1)2(1)2(1) data set to determine the NCS relating the eight
molecules in the asymmetric unit. However, despite trying
several different resolution limits and integration radii, no
clear NCS elements could be found using this data set. Cross-
rotation functions used a wide range of search models
including the monomer or dimer of either the L. mesenteroides
apoenzyme or its NADP+ binary complex. The inter-domain
hinge angles of these two structures are not identical owing to
binding of the coenzyme (Naylor, 1996). Search models
without the coenzyme-binding domains were also tested.
Models were also modi®ed by removing the loop regions or
the regions which were thought to be different from the
sequence alignment. Despite a series of attempts with various
resolution ranges and integration radii, none of these probes
was successful in solving the human structure in this space
group.
The phase problem of the type II C222(1) crystal was solved
rather more easily by molecular replacement. The cross-
rotation and translation search in AMoRe used a resolution
shell of 15±4.2 AÊ . The search model contained only the large
domains of the L. mesenteroides dimeric apoenzyme; the
radius of integration was set at 41 AÊ (0.8 times the radius of
the smallest sphere containing the whole molecule with the
origin at the centre of mass). The second highest peak (66% of
the maximum peak height) in the rotation function corre-
sponded to the ®rst peak in the one-body translation solution
in space group C2221, while the translational position of the
second dimer found corresponded to the ®rst peak in the
rotation function. The relative heights of the third and fourth
peaks in the rotation function were 60 and 57%; there were in
all 66 peaks more than 40% of the maximum. The translation
search failed in C222. The two-body solution in C2221
(correlation coef®cient = 28.1%, R factor = 49.6%) corre-
sponds to a tetramer placed in the cell so that it does not clash
with symmetry equivalents. The next possible two-body solu-
tion had a correlation coef®cient of 22.1% and a poorer R
factor. The tetramer is composed of two dimers, oriented `back
to back', with the dyad axes of the dimers coinciding. The self-
rotation function was also computed with re¯ections in the
resolution range 10±5 AÊ and the integration radius set to 20 AÊ .
It was compatible with the 222 NCS of the tetramer with two
of these axes close to the ab plane at 45 to a.
X-PLOR rigid-body re®nement was then carried out in
order to minimize any bad contact between the subunits and
to optimize the hinge angles between the coenzyme and large
domains. The residues used to de®ne the hinge were at the
conserved peptide, residues 198±205 in the human sequence;
residues before 200 were assigned as the coenzyme domain
and those after 200 were assigned as the large  +  domain.
The correlation coef®cients increased from 5.8 to 22.7% in the
test set and from 10.9 to 21.1% in the working set. The R factor
decreased from 54.6 to 52.2%, while the free R decreased from
55.4 to 54.3%. The ®rst electron-density map was generated
after non-crystallographic twofold averaging of the large
domain in each dimer and solvent ¯attening with the solvent
content set at 40% in DM. The coenzyme domain of the
human enzyme was clearly visible in this map.
The rigid-body re®ned tetramer from the C2221 cell
provided a new search model in the molecular replacement for
the 3.4 AÊ P2(1)2(1)2(1) data set. All the diffraction data in a
resolution range 15±3.5 AÊ were included and the integration
Table 1
Data processing and statistics for crystals G6PD R459L and G6PD.
Data sets 1 and 2 1, 2 and 4² 3 5
Crystal types I I II Ð
Crystals used 2 3 1 1
Wavelength (AÊ ) 0.87, 1.488³ 0.87, 1.488, 1.488³ 0.87 0.87
Space group P2(1)2(1)2(1) P212121 C222(1) F222
Unit-cell dimensions (AÊ )
a 128.9 128.9 123.8 60.8
b 208.7 208.7 170.6 172.5
c 214.3 214.3 284.4 217.2
G6PD molecules per asymmetric unit 8 8 4 1
Resolution (AÊ ) 25±3.4 25±3.0 30±4.0 30±2.5
Oscillation angle () 0.75, 0.5³ 0.75, 0.5, 1.0³ 1.25 1.0
Completeness (%) 93.3 84.3 86.3 73.3
95.5 (3.8±3.6 AÊ ) 80.1 (3.5±3.2 AÊ ) 89.0 (4.5±4.2 AÊ ) 65.6 (2.8±2.6 AÊ )
76.4 (3.6±3.4 AÊ ) 74.7 (3.2±3.0 AÊ ) 86.3 (4.2±4.0 AÊ ) 59.3 (2.6±2.5 AÊ )
Number of re¯ections 425336 647973 75948 115667
Number of unique re¯ections 74484 107584 21736 18730
I > 3(I) (%) 63.0 63.0 81.3 66.3
40.8 (3.8±3.6 AÊ ) 18.0 (3.5±3.2 AÊ ) 74.6 (4.5±4.2 AÊ ) 45.8 (2.8±2.6 AÊ )
23.6 (3.6±3.4 AÊ ) 11.7 (3.2±3.0 AÊ ) 60.2 (4.2±4.0 AÊ ) 35.6 (2.6±2.5 AÊ )
Rmerge (%) 14.6 11.1 12.9 12.5
39.4 (3.8±3.6 AÊ ) 28.9 (3.5±3.2 AÊ ) 22.6 (4.5±4.2 AÊ ) 19.7 (2.8±2.6 AÊ )
47.2 (3.6±3.4 AÊ ) 56.5 (3.2±3.0 AÊ ) 51.7 (4.2±4.0 AÊ ) 31.4 (2.6±2.5 AÊ )
Multiplicity§ 3.3 2.5 2.3 2.9
² A resolution range of 25±4.1 AÊ was used for the data sets 1 and 2, whereas a resolution range of 25±3.0 AÊ was used for the data set 4; the data sets were merged. ³ Values refer to the
components of the merged data set. § The average number of measurements for each re¯ection from which Rmerge was calculated.
radius was set to 47 AÊ in AMoRe. The rotation function
contained two closely related groups, each with four peaks of
heights 6.2±5.8 and 5.6±5.3. The next highest set of peaks
was 3.8. The translation function failed in space group
P21212. When space group P212121 was assigned, the best
solution (correlation coef®cient = 27.7%, R = 48.0%) corre-
sponded to one peak from the ®rst group (peak 2) and one
from the second group (peak 6) in the rotation function (with
peak heights 98 and 86% of the maximum, respectively). The
correlation coef®cients of alternative solutions were 18.5% or
less. The two tetramers deduced from the matrices were
labelled ABCD and EFGH. Rigid-body re®nement increased
the correlation coef®cient from 39.1 to 46.8% in the working
set and from 34.8 to 35.2% in the test set, and reduced the R
factor from 52.5 to 51.4% and Rfree from 53.1 to 52.1%. Non-
crystallographic eightfold averaging, treating the coenzyme
domains and the large domains separately, gave a much
improved map for subsequent model building.
Initial phases for the mutant G6PD in space group F222
were again obtained by molecular replacement. The search
model was a complete monomer from the partially re®ned
P212121 tetrameric human structure. The highest peak in the
rotation function (2.8 times the height of any other peak) gave
the correct solution of the translation function (correlation
coef®cient = 32.7% and R = 51.8%); the correlation coef®cient
for the next solution was 18.2%. Rigid-body re®nement
reduced the R factor from 57.7 to 56.8% and Rfree from 57.2 to
56.4% for re¯ections in the resolution range 15±2.5 AÊ . The
G6PD molecule found in this space group forms a 222
tetramer with crystallographic 222 symmetry.
3.4. Improvement of the model
The eightfold averaged P212121 map showed clearer density
in the large domain, especially in the sheet region near the
dimer axis, than in the coenzyme domain. The ®rst model was
built of a single subunit using this map; the subunit was used as
a protomer for the subsequent re®nement cycle. The model
consisting of 83.5% of the human sequence was then rigid-
body re®ned, followed by an X-PLOR constrained re®nement
against re¯ections in the resolution range 8±3.5 AÊ . Two groups
of NCS constraints, one for the coenzyme-binding domains
and one for the  +  domains, were used, thereby allowing
inter-domain hinge angles to vary. The values of R and Rfree
were re®ned to 30.5 and 33%, respectively. Further re®nement
of the model using the merged 3 AÊ data set gave an R factor of
31.1% and an Rfree of 34.9%. While NCS averaging enhances
the density of both coenzyme-binding and  +  domains, the
N-terminal region (1±26) is improved little and it is apparent
that these residues have different conformations in the
different subunits.
The ®rst model of G6PD contained 75% of the human
sequence. The ®rst re®nement cycle with re¯ections in the
resolution range 8±2.5 AÊ re®ned the R factor to 30.2% and
Rfree to 42.0%. At an intermediate stage of re®nement, R is
24.7% and Rfree 32.2%. Further re®nement for both mutant
enzymes is in progress.
3.5. Crystal packing
The R459L tetramers found by AMoRe have 222 symmetry
and the overall shape seen in electron micrographs of wild-
type G6PD (Wrigley et al., 1972). Each is formed by two
extended dimers positioned `back to back'. The molecules
pack in both C2221 and P212121 space groups with one
tetramer twofold along or close to the c axis and the other two
at approximately 45 to the a axis and to the b axis. In the
C2221 cell, the axis equivalent to the twofold of the L.
mesenteroides dimer lies in the ab plane, and the molecular
axis approximately parallel to c is, in fact, at 19 to it. Both
tetramers in the P212121 cell have one axis close to c (at
approximately 5 and 15 to it) and another within 5 of the ab
plane, making an angle of 40 to a (depending on the
symmetry equivalent considered). The smallest rotation which
places an ABCD tetramer onto an EFGH tetramer is
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Figure 3
Packing of tetramers in G6PD R459L and of G6PD. (a) G6PD R459L
in the P212121 cell, (b) G6PD R459L in the C2221 cell and (c) G6PD.
The similar orientations of NCS axes relative to cell axes and the
approximate pseudo-centring relating tetramers ABCD and EFGH in the
P212121 cell are apparent. While packing within the tetramer is similar for
G6PD, the tetramer±tetramer contacts are different. An attempt has
been made to represent the shape of the tetramer by using straight-line
segments which join the points of each monomer with maximum and
minimum coordinates in the directions of the three non-crystallographic
axes.
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approximately 13. The arrangements of the tetramers in the
two cells are shown schematically (Fig. 3). It is noteworthy that
both crystal forms are found for G6PD B under conditions
similar to those described here for the R459L variant; they are
effectively isomorphous to both the C2221 crystals and the
P212121 crystals.
The molecular arrangement of G6PD is much simpler; the
three molecular twofold axes are coincident with the cell axes
and the tetramer obeys the crystallographic 222 symmetry.
The L. mesenteroides dimer axis is directed along the b axis;
the tetramer is again formed by a `back to back' association of
dimers. As no R459L crystal can be grown under the crystal-
lization conditions of G6PD, it seems likely that the
presence of the N-terminal 25 residues and their mobility
prevents the R459L mutant from crystallizing in F222 with
exact 222 molecular symmetry. The dimeric L. mesenteroides
enzyme, which can exhibit exact twofold symmetry (Naylor,
1996), also lacks an N-terminal `tail'.
3.6. Repeat of molecular replacement with a dimeric search
model
Molecular replacement for the P212121 data was performed
again in order to understand the reasons which led to its
failure as described in x3.3. The search model used for this test
was the dimer of the L. mesenteroides G6PD large domains
oriented as dimer AB from the tetramer ABCD found in the
C2221 data (the successful tetrameric search model for the
P212121 data). Dimer AB was extracted from the output
coordinates after the `tabling' stage in AMoRe, in which the
centre of mass of the tetramer ABCD from C2221 data had
been placed at the origin and put into the cross-rotation search
for the P212121 data. This allowed a direct comparison of the
Eulerian angles from the rotation function with those using
the tetramer as a search probe.
It was found that the correct rotation angles to orient the
dimer in each tetramer were present in the list at positions 25
and 72 (Table 2). The probable solutions for another two
dimers were identi®ed by the 222 NCS of the tetramer. These
two solutions (peaks 22 and 34) have approximately 180
difference in the Eulerian angle  from peaks 25 and 72 and
map satisfactorily onto the second dimer of each tetramer.
This implies that a known tetramer should not have been a
prerequisite for solving the P212121 structure by molecular
replacement. However, the correct solutions are much further
down the list of possibilities than were the solutions for the
tetramer and they were clearly
dif®cult to recognize without addi-
tional information. The similarity
of the orientation angles for the
two tetramers further confuses the
solutions, as is evidenced by the
similar angles seen for peaks 22
and 34, which map onto different
tetramers. Finally, the special
nature of the solution in both cells
led to a highly symmetric self-
rotation function in C2221 and suf®cient broadening of the
peaks in P212121 so that the solution was obscured. Use of the
molecular symmetry found in the simpler centred cell for the
more complex problem has resulted in a satisfactory solution
for the human G6PD variant R459L.
One of the reasons for expressing and crystallizing G6PD
was to aid the solution of the human G6PD structure. As we
hoped, this molecule crystallized with 222 crystallographic
symmetry. The simpler molecular-replacement problem which
it presented could probably have been solved from the L.
mesenteroides G6PD monomer and the G6PD 222 tetramer
then used to solve the P212121 structure. It did not prove
necessary to follow this path; the partially re®ned tetramer of
the P212121 crystal form of G6PD Canton was a suitable search
model for G6PD.
This paper is the culmination of efforts for many years to
grow crystals of human G6PD which can be used for structural
studies. We are grateful for the support of earlier members of
the group working in Oxford, and particularly for the support,
time and expertise of members of the group at the Hammer-
smith Hospital and their collaborators: Dr L. M. Carmadella
(Naples) and Dr J. M. Bautista (Madrid). We are grateful to
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project. CEN was in receipt of a Wellcome Prize Fellowship.
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